Survival of patients with early-stage cervical cancer after abdominal or laparoscopic radical hysterectomy: a nationwide cohort study and literature review

Wenzel, Hans H B; Smolders, R.G.V.; Beltman, Jogchum Jan; Lambrechts, Sandrina; Trum, Hans; Yigit, Refika; Zusterzeel, Petra L.M.; Zweemer, Ronald P.; Mom, Constantijne H.; Bekkers, Ruud L.M.; Lemmens, Valery; Nijman, Hans W.; Aa, Maaike A. van der

doi:10.1016/j.ejca.2020.04.006

Cited by 63 publications

(63 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After reviewing the full text of the remaining 77 articles, we included 36 articles in the final analysis (41)(42)(43)(44)(45)(46). Forty studies were excluded from the final review ; they had no available survival outcome data (N = 19).…”

Section: Literature Searchmentioning

confidence: 99%

“…Study design Matched 10 (5,11,13,15,16,19,28,30,41,43) 1.49 (1.19-1.88) 0.001 27.5 Fixed effect Retrospective 26 (6-10, 12, 14, 17, 18, 20-27, 29, 31-34, 42, 44-46) 1. (12,13,19,23,24,(27)(28)(29)(30)(31)(32)(33)(34)(42)(43)(44)(45)(46) 1. Small (at least one arm < 90) 18 (5-11, 14-18, 20-22, 25, 26, 41) 0.90 (0.67-1.20)…”

Section: Fixed Effectmentioning

confidence: 99%

“…Before LACC trial 22 (5-24, 41, 42) 0.89 (0.71-1.11) 0.289 0.0 Fixed effect After LACC trial 14 (25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(43)(44)(45)(46) 1. 17 (5, 11, 12, 17, 19, 21, 22, 24-26, 29, 31, 32, 41-43, 45) 1.06 (0.87-1.30) 0.555…”

Section: Published Yearmentioning

confidence: 99%

“…Overweight (25 -30) 8 (6,9,10,15,20,23,33,46) 0.90 (0.67-1.21) 0.474 0.0 Fixed effect Unknown 11 (7,8,13,14,16,18,27,28,30,34,44) 1.68 (1.37-2.05) 0.000 0.0 Fixed effect Country Orient 20 (7, 11-13, 16, 18, 19, 21, 22, 25-29, 31, 32, 34, 42, 43, 45) 1.30 (1.10-1.54) 0.002 46.5 Fixed effect Occident 16 (5, 6, 8-10, 14, 15, 17, 20, 23, 24, 30, 33, 41, 44, 46) 1. Laparoscopic type TLRH 30 (7-9, 11, 12, 14-20, 22-34, 41-46) 1.29 (1.13-1.47) 0.000 34.1 Fixed effect LARVH 5 (5,6,10,13,21) 0 Supplementary file 2.…”

Section: Fixed Effectmentioning

confidence: 99%

See 3 more Smart Citations

Comparison of Survival Outcomes after Laparoscopic Radical Hysterectomy versus Abdominal Radical Hysterectomy in Patients with Cervical Cancer

Hwang

Kim

2021

Journal of Minimally Invasive Gynecology

View full text Add to dashboard Cite

Section: Literature Searchmentioning

confidence: 99%

Section: Fixed Effectmentioning

confidence: 99%

Section: Published Yearmentioning

confidence: 99%

Section: Fixed Effectmentioning

confidence: 99%

See 2 more Smart Citations

Comparison of Survival Outcomes after Laparoscopic Radical Hysterectomy versus Abdominal Radical Hysterectomy in Patients with Cervical Cancer

Hwang

Kim

2021

Journal of Minimally Invasive Gynecology

View full text Add to dashboard Cite

“…Therefore, the independent impact of centralisation and laparoscopy on survival cannot be determined. However, in contrast to Ramirez et al [18], laparoscopy was not associated with adverse oncological outcomes, in the Netherlands [19]. Chemoradiation for LACC was officially incorporated in the national guideline in 2004.…”

Section: Discussionmentioning

confidence: 92%

No improvement in survival of older women with cervical cancer—A nationwide study

Wenzel¹,

Bekkers²,

Lemmens³

et al. 2021

European Journal of Cancer

Self Cite

View full text Add to dashboard Cite

This study aims to report trends in primary treatment and survival in cervical cancer (CC) to identify opportunities to improve clinical practice and disease outcome. Methods: Patients diagnosed with CC between 1989 and 2018 were identified from the Netherlands Cancer Registry (N Z 21,644). Trends in primary treatment and 5-year relative survival were analysed with the Cochran-Armitage trend test and multivariable Poisson regression, respectively. Results: In early CC, surgery remains the preferred treatment for ages 15e74. Overall, it was applied more often in younger than in older patients (92% in 15e44; 64% in 65e74). For 75þ, surgery use was stable over time (38%e41%, pZ0.368), while administration of radiotherapy decreased (57%e29%, p < 0.001). In locally advanced CC, chemoradiation use increased over time (5%e65%, p < 0.001). It was applied least often for 75þ, in which radiotherapy remains most common (54% in 2014e2018). In metastatic CC, chemotherapy use increased over time (11%e28%, p < 0.001), but varied across age groups (6%e40% in 2014e2018). In patients treated with primary chemoradiation, regardless of stage, brachytherapy use increased over time (p 0.001). Full cohort 5-year survival increased from 68% to 74% (relative excess risk 0.55; 95% confidence interval [0.50e0.62]). Increases were most significant in locally advanced CC (38%e60%; 0.55 [0.47e0.65]). Survival remained stable in 75þ (38%e34%; 0.82 [0.66 e1.02]).

show abstract

Advances in cervical cancer: current insights and future directions

Xu,

Cao,

et al. 2024

Cancer Communications

View full text Add to dashboard Cite

In alignment with the World Health Organization's strategy to eliminate cervical cancer, substantial progress has been made in the treatment of this malignancy. Cervical cancer, largely driven by human papillomavirus (HPV) infection, is considered preventable and manageable because of its well‐established etiology. Advancements in precision screening technologies, such as DNA methylation triage, HPV integration detection, liquid biopsies, and artificial intelligence‐assisted diagnostics, have augmented traditional screening methods such as HPV nucleic acid testing and cytology. Therapeutic strategies aimed at eradicating HPV and reversing precancerous lesions have been refined as pivotal measures for disease prevention. The controversy surrounding surgery for early‐stage cervical cancer revolves around identifying optimal candidates for minimally invasive and conservative procedures without compromising oncological outcomes. Recent clinical trials have yielded promising results for the development of systemic therapies for advanced cervical cancer. Immunotherapies, such as immune checkpoint inhibitors (ICIs), antibody‐drug conjugates (ADCs), and targeted therapy have demonstrated significant effectiveness, marking a substantial advancement in cervical cancer management. Various combination therapies have been validated, and ongoing trials aim to enhance outcomes through the development of novel drugs and optimized combination regimens. The prospect of eradicating cervical cancer as the first malignancy to be eliminated is now within reach. In this review, we provide a comprehensive overview of the latest scientific insights, with a particular focus on precision managements for various stages of cervical disease, and explore future research directions in cervical cancer.

show abstract

Survival of patients with early-stage cervical cancer after abdominal or laparoscopic radical hysterectomy: a nationwide cohort study and literature review

Cited by 63 publications

References 28 publications

Comparison of Survival Outcomes after Laparoscopic Radical Hysterectomy versus Abdominal Radical Hysterectomy in Patients with Cervical Cancer

Comparison of Survival Outcomes after Laparoscopic Radical Hysterectomy versus Abdominal Radical Hysterectomy in Patients with Cervical Cancer

No improvement in survival of older women with cervical cancer—A nationwide study

Advances in cervical cancer: current insights and future directions

Contact Info

Product

Resources

About